While being based on recurrent clinically actionable genomic aberrations rather than on the assessment on TERT promoter mutations, a study reported that the use of urinary cfDNA led to higher analytical sensitivity (90%), as well as the use of urinary cellDNA (61%) for the detection of UC tumor-associated alterations [78]. This evidence concerns the gene TERT and neoplasm.